The mesolimbic dopaminergic system (ML-DA) allows adapted interactions with the
environment and is therefore of critical significance for the individual's survival. The ML-DA …

Objective: To describe the association of specific medication classes with driving outcomes
and provide clinical recommendations. Data Sources: The MEDLINE and EMBASE …

Dopamine receptor agonists are indicated for the symptomatic treatment of early, moderate
or advanced Parkinson's disease as well as for the reduction of levodopa-related motor …

Apart from the typical motor symptoms, Parkinson's disease is characterized by a wide range
of different non-motor symptoms, which are highly prevalent in all stages of the disease and …

Insomnia is an ordinary situation related to noticeable disability in function and quality of life,
mental and actual sickness, and mishappenings. It represents more than 5.5 million …

Excessive daytime sleepiness is a disabling and vital problem in patients with PD. It affects
around 33% patients and culminates in sleep attacks (without prodroma) in 1 to 4% of the …

Though l-3, 4-dihydroxyphenylalanine (L-DOPA) is universally employed for alleviation of
motor dysfunction in Parkinson's disease (PD), it is poorly-effective against co-morbid …

The spectrum of sleep problems in Parkinson's disease (PD) is broad. These symptoms are
recognized as being clinically relevant by the PD patients and may seriously affect their …

Pharmacological cognitive enhancement refers to improvement in cognitive functions after
drug use in healthy individuals. This popular topic attracts attention both from the general …

The aim of this study was to identify changes of sleep spindles (SS) in the EEG of patients
with Parkinson's disease (PD). Five sleep experts manually identified SS at a central scalp …